Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs*
Diagnosis and Treatment of Myxomatous Mitral Valve Disease in Dogs
Canine myxomatous mitral valve disease (MMVD) is very common in veterinary practice. Due to strong breed predispositions, it is easy to identify dogs that are at risk for the development of this disease. Additionally, as clinically significant disease is reliably associated with a left apical systolic heart murmur, identification of affected dogs is relatively straightforward. Historically, management recommendations for dogs at risk of disease development or with preclinical disease, centred on monitoring and estimating the risk of congestive heart failure developing in the future. Treatment was not recommended until the onset of congestive heart failure. However, the EPIC study demonstrated that treatment with pimobendan in dogs with cardiomegaly secondary to preclinical MMVD, delays the onset of congestive heart failure (Boswood et al.2016). This has resulted in a paradigm shift in recommendations for management of this disease. Updated recommendations were recently published by the American College of Veterinary Internal Medicine (ACVIM) and are summarised in this review (Keene et al.2019).
All our Tutored Online CPD Courses are written and taught by an expert in the relevant field. The tutor for this course is:
Melanie Hezzell MA, VetMB, PhD, CertVDI, CertVC, FHEA, MRCVS, DipACVIM (Cardiology) RCVS and American Specialist in Veterinary Cardiology